{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T12:45:22Z","timestamp":1758631522669},"reference-count":64,"publisher":"Elsevier BV","issue":"1","content-domain":{"domain":["bprch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.beha.2013.04.005","type":"journal-article","created":{"date-parts":[[2013,5,25]],"date-time":"2013-05-25T09:45:40Z","timestamp":1369475140000},"page":"43-56","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Treatment strategies for peripheral T-cell lymphomas"],"prefix":"10.1016","volume":"26","author":[{"given":"Francine M.","family":"Foss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.beha.2013.04.005_bib1","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma","volume":"89","author":"The Non-Hodgkin's Lymphoma Classification Project","year":"1997","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.beha.2013.04.005_bib2","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"The International T-Cell Lymphoma Project","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2013.04.005_bib3","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1309\/NW2BK1DXB0EQG55H","article-title":"Enteropathy-type T-cell lymphoma","volume":"127","author":"Zettl","year":"2007","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"10.1016\/j.beha.2013.04.005_bib4","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1182\/blood-2007-04-087288","article-title":"Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases","volume":"111","author":"Willemze","year":"2008","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2013.04.005_bib5","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1080\/10428190802455867","article-title":"Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States","volume":"49","author":"Abouyabis","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1016\/j.beha.2013.04.005_bib6","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/cncr.20999","article-title":"Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience","volume":"103","author":"Escalon","year":"2005","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.beha.2013.04.005_bib7","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/annonc\/mdn022","article-title":"Intensive chemotherapy (high-dose CHOP\/ESHAP regimen) followed by autologous\u00a0stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma","volume":"19","author":"Mercadal","year":"2008","journal-title":"Ann Oncol"},{"issue":"18","key":"10.1016\/j.beha.2013.04.005_bib8","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.beha.2013.04.005_bib9","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1182\/blood-2003-02-0542","article-title":"Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma","volume":"102","author":"Tilly","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2013.04.005_bib10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2141.2010.08329.x","article-title":"Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP\/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95","volume":"151","author":"Simon","year":"2010","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.beha.2013.04.005_bib11","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3324\/haematol.10767","article-title":"Expression of CD52 in peripheral T-cell lymphoma","volume":"92","author":"Piccaluga","year":"2007","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.beha.2013.04.005_bib12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00280-007-0469-9","article-title":"Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study","volume":"60","author":"Kim","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"10.1016\/j.beha.2013.04.005_bib13","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","article-title":"Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial","volume":"110","author":"Gallamini","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2013.04.005_bib14","doi-asserted-by":"crossref","first-page":"33348","DOI":"10.1182\/blood.V106.11.3348.3348","article-title":"A pilot study of Campath-1 with dose-adjusted EPOCH in CD52 expressing aggressive T-cell malignancies","volume":"106","author":"Janik","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2013.04.005_bib15","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2141.2006.06457.x","article-title":"Phase II trial of denileukin diftitox for relapsed\/refractory T-cell non-Hodgkin lymphoma","volume":"136","author":"Dang","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2013.04.005_bib16","doi-asserted-by":"crossref","unstructured":"Foss FM, Sjak-Shie NN, Goy A, Advani R, Jacobsen ED. Phase II study of denileukin diftitox with CHOP chemotherapy in newly-diagnosed PTCL: CONCEPT trial. ASCO Meet Abstr;28(15_suppl):8045.","DOI":"10.1200\/jco.2010.28.15_suppl.8045"},{"issue":"11","key":"10.1016\/j.beha.2013.04.005_bib17","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1038\/sj.leu.2403936","article-title":"Complete remission in a patient with relapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab","volume":"19","author":"Bruns","year":"2005","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.beha.2013.04.005_bib18","first-page":"1671","article-title":"Cardiac toxicity associated with the anti-VEGF monoclonal antibody bevacizumab (Avastin) in combination with CHOP (A-CHOP) chemotherapy for peripheral T cell lymphoma (PTCL): the ECOG 2404 trial","volume":"114","author":"Advani","year":"2009","journal-title":"Blood (ASH Annu Meet Abstr)"},{"issue":"4","key":"10.1016\/j.beha.2013.04.005_bib19","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/annonc\/mdp508","article-title":"Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome","volume":"21","author":"Zinzani","year":"2010","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.beha.2013.04.005_bib20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3324\/haematol.10737","article-title":"Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience","volume":"92","author":"Arkenau","year":"2007","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.beha.2013.04.005_bib21","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1445-5994.2007.01397.x","article-title":"Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim","volume":"37","author":"Spencer","year":"2007","journal-title":"Intern Med J"},{"issue":"1","key":"10.1016\/j.beha.2013.04.005_bib22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00280-005-0136-y","article-title":"CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas","volume":"58","author":"Kim","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.beha.2013.04.005_bib23","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s11899-009-0031-4","article-title":"Hemopoietic stem cell transplantation in T-cell malignancies: who, when, and how?","volume":"4","author":"d'Amore","year":"2009","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"10.1016\/j.beha.2013.04.005_bib24","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2013.04.005_bib25","first-page":"937a","article-title":"Phase I trial of siplizumab in CD2-positive lymphoproliferative disease","volume":"106","author":"O'Mahony","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2013.04.005_bib26","first-page":"1043a","article-title":"EBV-related lymphoproliferative disease complicating therapy with siplizumab, a novel anti-CD2 mediated T- and NK-cell depleting agent, in patients with T-cell malignancies","volume":"110","author":"O'Mahony","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2013.04.005_bib27","doi-asserted-by":"crossref","first-page":"771a","DOI":"10.1182\/blood.V108.11.2727.2727","article-title":"A phase I open label dose escalation study to evaluate MEDI-507 in patients with CD2-positive T-cell lymphoma\/leukemia","volume":"108","author":"Casale","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2013.04.005_bib28","first-page":"999z","article-title":"Zanolimumab (HuMax-CD4\u2122), a fully human monoclonal antibody: efficacy and safety in patients with relapsed or treatment-refractory non-cutaneous CD4+ T-cell lymphoma","volume":"110","author":"d'Amore","year":"2007","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2013.04.005_bib29","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1200\/JCO.2000.18.8.1622","article-title":"Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies","volume":"18","author":"Kreitman","year":"2000","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2013.04.005_bib30","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2141.2009.07740.x","article-title":"A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma","volume":"146","author":"Forero-Torres","year":"2009","journal-title":"Br J Haematol"},{"issue":"19","key":"10.1016\/j.beha.2013.04.005_bib31","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1200\/JCO.2006.07.8972","article-title":"Phase I\/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma","volume":"25","author":"Ansell","year":"2007","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.beha.2013.04.005_bib32","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1182\/blood-2003-02-0515","article-title":"The human anti-CD30 antibody 5F11 shows in\u00a0vitro and in\u00a0vivo activity against malignant lymphoma","volume":"102","author":"Borchmann","year":"2003","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.beha.2013.04.005_bib33","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2013.04.005_bib34","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood-2007-07-099317","article-title":"A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies","volume":"111","author":"Bartlett","year":"2008","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.beha.2013.04.005_bib35","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2013.04.005_bib36","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1200\/JCO.2009.25.3575","article-title":"Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma","volume":"28","author":"Yamamoto","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2013.04.005_bib37","doi-asserted-by":"crossref","unstructured":"Ishida T, Joh T, Uike N, et\u00a0al. Multicenter phase II study of KW-0761, a defucosylated anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma (ATL). Blood (ASH Annu Meet Abstr);116(21):285.","DOI":"10.1182\/blood.V116.21.285.285"},{"issue":"7","key":"10.1016\/j.beha.2013.04.005_bib38","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s12094-008-0221-x","article-title":"Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer","volume":"10","author":"Martinez-Iglesias","year":"2008","journal-title":"Clin Transl Oncol"},{"issue":"21","key":"10.1016\/j.beha.2013.04.005_bib39","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2013.04.005_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2013.38","article-title":"Phase Ia\/II, 2-arm, open-label, dose-escalation study of oral panobinostat administered via 2 dosing schedules in patients with advanced hematologic malignancies","author":"Deangelo","year":"2013","journal-title":"Leukemia"},{"issue":"29","key":"10.1016\/j.beha.2013.04.005_bib41","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.beha.2013.04.005_bib42","first-page":"1657","article-title":"Final results of a phase 2 NCI multicenter study of romidepsin in patients with relapsed peripheral T-cell lymphoma (PTCL)","volume":"114","author":"Piekarz","year":"2009","journal-title":"Blood (ASH Annu Meet Abstr)"},{"issue":"6","key":"10.1016\/j.beha.2013.04.005_bib43","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.beha.2013.04.005_bib44","first-page":"920","article-title":"Final results of a phase II trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma","volume":"114","author":"Pohlman","year":"2009","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.beha.2013.04.005_bib45","doi-asserted-by":"crossref","unstructured":"Marchi E, Bongero DC, Kalac M, Scotto L, O'Connor OA. The combination of histone deacetylase inhibitors and hypomethylating agents exhibits marked synergy in preclinical models of T-cell lymphoma. Blood (ASH Annu Meet Abstr);116(21):3937.","DOI":"10.1182\/blood.V116.21.3937.3937"},{"issue":"3","key":"10.1016\/j.beha.2013.04.005_bib46","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1365-2141.2007.06658.x","article-title":"Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma","volume":"139","author":"O'Connor","year":"2007","journal-title":"Br J Haematol"},{"issue":"26","key":"10.1016\/j.beha.2013.04.005_bib47","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1200\/JCO.2008.20.8470","article-title":"Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies","volume":"27","author":"O'Connor","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.beha.2013.04.005_bib48","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.beha.2013.04.005_bib49","first-page":"1681","article-title":"Correlation between baseline methylmalonic acid status and mucositis severity in the PROPEL Study: implications for vitamin prophylaxis","volume":"114","author":"Pro","year":"2009","journal-title":"Blood (ASH Annu Meet Abstr)"},{"issue":"3","key":"10.1016\/j.beha.2013.04.005_bib50","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1080\/10428190601137658","article-title":"Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine","volume":"48","author":"Advani","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"15S","key":"10.1016\/j.beha.2013.04.005_bib51","first-page":"8524","article-title":"Activity of lenalidomide in a phase II trial for T-cell lymphoma: report on the first 24 cases","volume":"27","author":"Dueck","year":"2009","journal-title":"ASCO Meet Abstr"},{"issue":"Suppl. 2","key":"10.1016\/j.beha.2013.04.005_bib52","first-page":"S103","article-title":"Clinical experience with 2\u2032-deoxycoformycin","volume":"38","author":"Catovsky","year":"1996","journal-title":"Hematol Cell Ther"},{"issue":"2 Suppl. 2","key":"10.1016\/j.beha.2013.04.005_bib53","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1053\/j.seminhematol.2005.12.008","article-title":"Role of single-agent purine analogues in therapy of peripheral T-cell lymphomas","volume":"43","author":"Dearden","year":"2006","journal-title":"Semin Hematol"},{"issue":"27","key":"10.1016\/j.beha.2013.04.005_bib54","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2007.11.4207","article-title":"Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"25","author":"Zinzani","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2013.04.005_bib55","first-page":"112","article-title":"Pralatrexate (PDX) compliments the activity of the proteasome inhibitor bortezomib (B) in in\u00a0vitro models of lymphoid T-cell malignancies","author":"Marchi","year":"2008","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2013.04.005_bib56","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/sj.jid.5700322","article-title":"The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway","volume":"126","author":"Querfeld","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.beha.2013.04.005_bib57","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1200\/jco.2011.29.15_suppl.6631","article-title":"Phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3 kinase P110\u03b4, in patients with previously treated chronic lymphocytic leukemia","volume":"29","author":"Coutre","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2013.04.005_bib58","doi-asserted-by":"crossref","unstructured":"Jantunen E, Relander T, Lauritzsen GF, et\u00a0al. Intensive induction chemotherapy followed by autologous stem cell transplantation (ASCT) in patients with enteropathy-associated T-cell lymphoma: a prospective Study by the Nordic Lymphoma Group (NLG-T-01). Blood (ASH Annu Meet Abstr);116(21):3565.","DOI":"10.1182\/blood.V116.21.3565.3565"},{"issue":"6","key":"10.1016\/j.beha.2013.04.005_bib59","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/cncr.20502","article-title":"Immunophenotypic and molecular features, clinical outcomes, treatments, and prognostic factors associated with subcutaneous panniculitis-like T-cell lymphoma: a systematic analysis of 156 patients reported in the literature","volume":"101","author":"Go","year":"2004","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.beha.2013.04.005_bib60","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1097\/00000478-199807000-00010","article-title":"Subcutaneous panniculitis-like T-cell lymphoma: clinicopathologic, immunophenotypic, and genotypic analysis of alpha\/beta and gamma\/delta subtypes","volume":"22","author":"Salhany","year":"1998","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"10.1016\/j.beha.2013.04.005_bib61","first-page":"3750","article-title":"Outcomes in subcutaneous panniculitis-like T-cell lymphoma (STCL)","volume":"112","author":"Alpdogan","year":"2008","journal-title":"Blood (ASH Annu Meet Abstr)"},{"issue":"3","key":"10.1016\/j.beha.2013.04.005_bib62","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1080\/10428190601078456","article-title":"Cyclosporin in subcutaneous panniculitis-like T-cell lymphoma","volume":"48","author":"Rojnuckarin","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.beha.2013.04.005_bib63","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbmt.2008.04.004","article-title":"Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience","volume":"14","author":"Chen","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"25","key":"10.1016\/j.beha.2013.04.005_bib64","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d'Amore","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692613000066?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692613000066?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T05:26:24Z","timestamp":1715405184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692613000066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S1521692613000066"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2013.04.005","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment strategies for peripheral T-cell lymphomas","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2013.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}